Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data

Keitaro Shimozaki, Yasutaka Sukawa, Yasunori Sato, Sara Horie, Akihiko Chida, Kai Tsugaru, Kazuhiro Togasaki, Kenta Kawasaki, Kenro Hirata, Hideyuki Hayashi, Yasuo Hamamoto, Takanori Kanai

研究成果: Article査読

抄録

The aim of this study was to determine the risk factors for immune-related adverse events (irAEs) induced by immune checkpoint inhibitors. The authors conducted a retrospective study in which patients with malignant melanoma, non-small-cell lung cancer, gastric cancer or renal cell carcinoma who received anti-PD-1/PD-L1 antibodies were included. Of 247 patients, 118 developed a total of 182 irAEs. In the multivariate Fine-Gray regression analysis, serum albumin level ≥3.6 g/dl (hazard ratio: 1.62; 95% CI: 1.10-2.39; p = 0.015) and history of Type I hypersensitivity reactions (hazard ratio: 1.48; 95% CI: 1.02-2.14; p = 0.037) were significantly associated with the development of irAEs. High serum albumin levels and history of Type I hypersensitivity reactions are risk factors for irAEs.

本文言語English
ページ(範囲)2593-2603
ページ数11
ジャーナルFuture Oncology
17
20
DOI
出版ステータスPublished - 2021 7

ASJC Scopus subject areas

  • 腫瘍学
  • 癌研究

フィンガープリント

「Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル